C H4 S O3 SMILES O=C(N1CCC2(C(C=CC=C3)=C3N(S(C)(=O)=O)C2)CC1)[C@H](NC(C(C)(N)C)=O)COCC4=CC=CC=C4.OS(=O)(C)=O InChI InChI=1S/C27H36N4O5S.CH4O3S/c1-26(2,28)25(33)29-22(18-36-17-20-9-5-4-6-10-20)24(32)30-15-13-27(14-16-30)19-31(37(3,34)35)23-12-8-7-11-21(23)27;1-5(2,3)4/h4-12,22H,13-19,28H2,1-3H3,(H,29,33);1H3,(H,2,3,4)/t22-;/m1./s1 IUPAC 2-amino-N-[(1R)-2-[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl-propanamide, methanesulfonate Product Data Storage Temperature -20C Shipping Temperature Room Temperature Product Type Bioactive small molecule
Note that supplementary treatment with NAC could rescue the decrease in IL-17A production upon SFN treatment
Furthermore, GLS1 has been associated with a poor patient prognosis
Unlike aromatase inhibitors, it does not reduce overall estrogen levels, but instead selectively prevents estrogen from activating receptors where it is most problematic
10.12659/MSM.908936 154 WangF.ChenL.KongD.ZhangX.XiaS.LiangB.et al (2024a)